Healthcare evidence-generation and technology company uMed have announced the successful enrollment of over 2,000 participants into their AccessCMD Cardiometabolic Cohort less than 4 months after starting enrollment. The exponential growth of the cohort within this short time frame highlights the commitment of patients within this disease area to engage in research, and showcases the effectiveness of uMed’s unique model in providing research access that has previously been unavailable. AccessCMD is a novel decentralised registry and...